Table 2.
Characteristics of antibodies directed to LSAs.
| Target | mAb (commercial name/originator) | IgG class | MOA | Active indications in HMs (highest phase) | Reference |
|---|---|---|---|---|---|
| CD19 | Inebilizumab, MEDI 551 (Cellective Therapeutics) | Hz IgG1 | ADCC | II (CLL/NCT01466153 aC) | (31) |
| Glyco-Fc | CDC | II (DLBCL/NCT01453205 aC) disc. | |||
| ADCP | I–II (B-NHL/NCT02271945 aC) | ||||
| I (MM/NCT01861340 aC) | |||||
| MOR00208, XmAb5574 (Xencor) | Hz IgG1 | ADCC | III (DLBCL/NCT02763319 aR) | (24, 32) | |
| ADCP | II (BALL/NCT02763319 bT) | ||||
| PCD | II (CLL/NCT02639910 aR) | ||||
| II (B-NHL/NCT01685008 bANR) | |||||
| MDX-1342 (Medarex) | Fh IgG1 | ADCC | I (CLL/NCT00593944 bC) | (33) | |
| Glyco-Fc | |||||
| CD22 | Epratuzumab, AMG-412, IMMU-103 (Immunomedics) | Hz IgG1 | ADCC | II (B-ALL/NCT01802814 bR) | (25) |
| PCD | III (B-NHL/NCT00022685 bC) | ||||
| Alterations in CD22 and BCR signaling its action | II (FL/NCT00553501 aC) | ||||
Antibodies that reached clinical studies. Biosimilars and immunoconjugates are excluded.
aCombined therapy.
bMonotherapy.
mAb, monoclonal antibody; MOA, mechanisms of action; HMs, hematological malignancies; Ch, human–mouse chimeric; Fh, hully human; Hz, humanized; Glyco-Fc, glycoengineered Fc fragment; CDC, complement-dependent cytotoxicity; ADCC, antibody-dependent cell-mediated cytotoxicity; ADCP, antibody-dependent cell-mediated phagocytosis; PCD, programmed cell death; B-NHL, B-cell non-Hodgkin’s lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; MM, multiple myeloma; FL, follicular lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; BCR, B-cell receptor; DISC., discontinued; NCT, number of clinical trial (clinicaltrials.gov); C, completed; R, recruiting; T, terminated; ANR, active non-recruiting.